Search In this Thesis
   Search In this Thesis  
العنوان
Radical surgery followed by intra-operative hyperthermic intrathoracic chemotherapy versus radical surgery alone for treatment of malignant pleural mesothelioma :
الناشر
Amr Mahmoud Aldemery ,
المؤلف
Amr Mahmoud Aldemery
هيئة الاعداد
باحث / Amr Mahmoud Aldemery
مشرف / Abdel Rahman Mohammed Abdelrahman
مشرف / Ismail Abdel Moneim Mourad
مشرف / Rabab Mohammed Gaafar
تاريخ النشر
2019
عدد الصفحات
100 P. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
علم الأورام
تاريخ الإجازة
13/11/2019
مكان الإجازة
جامعة القاهرة - معهد الأورام القومى - surgical oncology
الفهرس
Only 14 pages are availabe for public view

from 126

from 126

Abstract

Patients: This is a prospective study that included two groups of patients diagnosed with malignant pleural mesothelioma, study group (group A) that underwent radical surgery combined with hyperthermic intrathoracic chemotherapy ”20 patients”, and control group (group B) who underwent radical surgery alone ”20 patients”, during the study period from January 2017 to December 2018 at the National Cancer Institute, Cairo university, Egypt. Methods: Criteria of the patients, with the operative details as type of surgical procedure (EPP or P/D), side, and intra-operative sequelae during HITHOC as technical, cardiovascular and respiratory complications were analysed. Pathological TNM staging was described. Early and late postoperative complications were investigated. Patients were followed-up during the study period. Results: Our study included 15 males and 5 females in each arm. Their median age was 48.2 (HITHOC arm) & 52 (Control arm). Mean length of hospital stay of patients undergoing HITHOC was 10.1 (range: 7-17 days), while that of control group was 11.4 (range: 8-25 days). Atrial fibrillation, that occurred in 6 patients receiving HITHOC (30%) and 5 patients in the control group (25%), was the most commonly observed morbidity. (35%) patients who had received HITHOC had experienced MPM recurrence during the follow up period, and the 1-year Disease Free Survival (DFS) was 68.8%, in comparison to the control group, in which 10 patients (50%) had disease relapse, and 1-year DFS was 44%